03 Profile
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Annie Kennedy
Chief Mission Officer of the EveryLife Foundation for Rare Diseases
press citation on 1 topic since 3 Mar 2026 · last quoted 3 Mar 2026
02 Quoted on · 1 of 29 topics
Annie Kennedy: key facts
- Kind of voice
- Sector leader
- Role
- Chief Mission Officer of the EveryLife Foundation for Rare Diseases
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 3 Mar 2026
04 The signal · where Annie Kennedy sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Dr Emma BoxleyClinicianDoctor, University College London global health researcher1
- 25=Dr Dragana JosifovaClinicianConsultant in clinical genetics at Guy's and St Thomas' NHS Trust in London1
- 25=Annie KennedySector leaderChief Mission Officer of the EveryLife Foundation for Rare Diseases1
- 25=Pamela HealySector leaderChief Executive of the British Liver Trust1
- 25=Dr Danielle FreedmanClinicianConsultant Chemical Pathologist & Deputy Medical Director1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Annie Kennedy has said
- axios.com1
Where Annie Kennedy has been quoted
- 01FDA slammed over rare disease drug decisions. Here's whyaxios.com · 3 Mar 2026
Verbatim
“Our community has experienced a series of FDA actions on rare disease product applications that seem misaligned with recent public pledges to expand the use of regulatory flexibility in evaluating rare disease therapies”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.